Financial Performance - For Q3 2024, operating expenses totaled $5.3 million, a decrease of $0.6 million or 10.5% compared to Q3 2023[12] - Net losses for Q3 2024 were $4.9 million, compared to $5.3 million in Q3 2023[14] - Basic and diluted loss per share attributable to common stockholders was $0.59 for Q3 2024, compared to $0.65 for Q3 2023[21] - The net loss for Q3 2024 was $4,930,000, compared to a net loss of $5,261,000 in Q3 2023, reflecting a 6.3% improvement[21] - Investment income for Q3 2024 was $451,000, a decrease from $714,000 in Q3 2023[21] Research and Development - Research and development expenses were approximately $2.5 million, down $0.8 million or 24.8% from $3.4 million in Q3 2023, primarily due to reduced clinical research organization expenses[13] - Research and development expenses for Q3 2024 were $2,542,000, a decrease of 25% from $3,380,000 in Q3 2023[21] - The ASCEND trial is a Phase 2b study evaluating certepetide in combination with SoC chemotherapy for metastatic pancreatic ductal adenocarcinoma, with data from 95 patients expected in January 2025[3] - The BOLSTER trial achieved complete enrollment in first-line cholangiocarcinoma nearly six months ahead of schedule, with topline data anticipated in mid-2025[4] - The CENDIFOX trial is expected to complete enrollment in pancreatic, colon, and appendiceal cancer cohorts by the end of 2024[6] - Lisata has entered into research collaborations to assess certepetide in combination with other therapies for endometriosis and melanoma[11] - Certepetide has received Fast Track designation and Orphan Drug Designation for multiple cancer types, including pancreatic cancer and glioma[3] - The company anticipates a data-rich 2025 with multiple key data readouts projected over the next 18 months[2] Cash and Assets - As of September 30, 2024, cash, cash equivalents, and marketable securities amounted to approximately $35.9 million, expected to fund operations into early 2026[15] - Cash, cash equivalents, and marketable securities decreased to $35,856,000 as of September 30, 2024, from $50,535,000 at the end of 2023[22] - Total assets decreased to $38,199,000 as of September 30, 2024, down from $54,694,000 at the end of 2023[22] - Total liabilities decreased to $4,763,000 as of September 30, 2024, from $6,800,000 at the end of 2023[22] - Total equity decreased to $33,436,000 as of September 30, 2024, down from $47,894,000 at the end of 2023[22] Operating Expenses - General and administrative expenses increased to $2,794,000 in Q3 2024 from $2,584,000 in Q3 2023, representing an 8% increase[21] - Total operating expenses for Q3 2024 were $5,336,000, down 10.5% from $5,964,000 in Q3 2023[21]

Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the third q ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors, including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [3][4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [4]

Core Insights - Lisata Therapeutics and Valo Therapeutics have initiated a preclinical research collaboration to explore the combination of Lisata's certepetide and ValoTx's PeptiCRAd platform technology in melanoma treatment [1][2] - The collaboration aims to enhance patient outcomes by addressing challenges in current melanoma therapies, such as resistance and metastasis [2] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [4] - Certepetide, Lisata's investigational drug, selectively activates a transport mechanism to improve the delivery of anti-cancer agents to tumors and modifies the tumor microenvironment [3][4] - Certepetide has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers, indicating its potential in treating serious conditions [3] Valo Therapeutics Overview - Valo Therapeutics is an immunotherapy company developing tumor antigen-coated replication-competent viruses as therapeutic vaccines against cancer [6] - The PeptiCRAd platform is designed to activate the tumor microenvironment and elicit broad immune responses against multiple tumor antigens [5][6] - ValoTx's lead product, PeptiCRAd-1, is currently in Phase 1 clinical testing for various cancers, including melanoma [5]

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [4] - The company is advancing its investigational drug, certepetide, which utilizes a novel uptake pathway to enhance the effectiveness of anti-cancer drugs targeting solid tumors [4] Financial Results Announcement - The company will report its financial results for the third quarter ended September 30, 2024, on November 12, 2024, after the market closes [1] - A conference call will be held at 4:30 p.m. Eastern time on the same day to discuss the results [1] Conference Call Participation - Interested participants must register for the conference call via a provided link and will receive an email with dial-in details [2] - To ensure a smooth experience, participants are encouraged to join the call 15 minutes early [2] Webcast Availability - A live webcast of the conference call will be available on Lisata's website and can be replayed for 12 months after the event [3] Future Expectations - The company anticipates announcing several milestones over the next 1.5 years and believes its projected capital will sustain operations into early 2026, covering expected data milestones from ongoing and planned clinical trials [4]

Core Insights - Lisata Therapeutics is collaborating with the University of Cincinnati to investigate a treatment for endometriosis using Certepetide, a novel cyclic peptide that targets integrins and neuropilin receptors elevated in both solid tumors and endometriosis [1][2]. Company Overview - Certepetide is a nine-amino-acid cyclic peptide that enhances the penetration of anti-cancer drugs in the tumor microenvironment and modifies the immunosuppressive environment by reducing regulatory T cells and increasing cytotoxic T cells [2][3]. - The partnership aims to evaluate the effectiveness of combining Certepetide with the anti-VEGF drug bevacizumab (Avastin) in reducing endometrial lesions and associated pain [3][4]. Research Details - The study will utilize a mouse model developed by the University of Cincinnati, involving approximately 60 mice divided into six groups to test two different doses of bevacizumab alongside intravenous Certepetide [4]. - The experiment will last six weeks, with three weeks for lesion development followed by three weeks of treatment, after which the lesion burden will be assessed [4]. Industry Context - Endometriosis affects about 10% of women of reproductive age globally, translating to approximately 190 million women, and is often under-recognized despite causing severe pain and other life-impacting symptoms [5]. - Current treatments are primarily symptomatic, including non-steroidal analgesics, hormonal modulators, and surgery, indicating a significant unmet need for more effective therapies [5].

Lisata Therapeutics, Inc. (LSTA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

Company Events - Lisata Therapeutics will participate in several upcoming events in November 2024, including BIO-Europe, PEGS Europe Summit, and LSX Inv€$tival showcase [1][2][3] - At BIO-Europe, Tariq Imam, Vice President of Business Development and Operations, will engage in one-on-one meetings [1] - David J. Mazzo, PhD, President and CEO, will present at PEGS Europe on November 5, 2024, at 3:20 p.m. CEST [2] - David J. Mazzo will also present at the LSX Inv€$tival showcase on November 18, 2024, at 1:00 p.m. GMT [3] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [4] - The company's investigational drug, certepetide, utilizes a novel uptake pathway to enhance the targeting and penetration of anti-cancer drugs in solid tumors [4] - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology and anticipates announcing multiple milestones over the next 1.5 years [4] - The company projects that its capital will support operations into early 2026, covering expected data milestones from ongoing and planned clinical trials [4]

BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treat ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...